neo penotran forte

Phase 2Small molecule

UUniversity of Alabama at Birmingham

neo penotran forte is one of 3 small molecule programs targeting Trichomoniasis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

TrichomoniasisActive, not recruiting

TrichomoniasisPhase 2

Active, not recruiting

Competition

Competitive Landscape

2 competitors in Trichomoniasis

#DrugCompanyPhaseTrials

Flagyl

DDePuy Orthopaedics

Phase 2

1 2

Solosec

EEvofem Inc.

Phase 3

1 3

neo penotran forte

UUniversity of Alabama at Birmingham

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Trichomoniasis1 trial

Neo-Penotran Forte Vaginal Suppository for Vaginal Trichomoniasis

Completed·UUniversity of Alabama at Birmingham·Phase 2·NCT01361048·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for neo penotran forte. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — neo penotran forte compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for neo penotran forte. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Alabama at Birmingham company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity of Alabama at Birmingham

neo penotran forte

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Trichomoniasis1 trial

References

Drug Info

Quick Facts

Related News